KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cash from Operations (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Cash from Operations data on record, last reported at 21980000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations rose 51.55% year-over-year to 21980000.0; the TTM value through Dec 2025 reached 75655000.0, up 140.4%, while the annual FY2025 figure was 75655000.0, 140.4% up from the prior year.
  • Cash from Operations reached 21980000.0 in Q4 2025 per RIGL's latest filing, down from 24031000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 55216000.0 in Q2 2021 and bottomed at 25637000.0 in Q1 2022.
  • Average Cash from Operations over 5 years is 1675150.0, with a median of 2716500.0 recorded in 2023.
  • Peak YoY movement for Cash from Operations: plummeted 545.17% in 2021, then soared 10011.59% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 19086000.0 in 2021, then dropped by 14.79% to 21909000.0 in 2022, then surged by 71.52% to 6240000.0 in 2023, then soared by 332.42% to 14503000.0 in 2024, then skyrocketed by 51.55% to 21980000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 21980000.0 in Q4 2025, 24031000.0 in Q3 2025, and 30537000.0 in Q2 2025.